DE602006019582D1 - Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen - Google Patents

Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen

Info

Publication number
DE602006019582D1
DE602006019582D1 DE602006019582T DE602006019582T DE602006019582D1 DE 602006019582 D1 DE602006019582 D1 DE 602006019582D1 DE 602006019582 T DE602006019582 T DE 602006019582T DE 602006019582 T DE602006019582 T DE 602006019582T DE 602006019582 D1 DE602006019582 D1 DE 602006019582D1
Authority
DE
Germany
Prior art keywords
adarb2
disease
alzheimer
diagnostic
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006019582T
Other languages
English (en)
Inventor
Johannes Pohlner
Der Kammer Heinz Von
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec Neurosciences GmbH
Original Assignee
Evotec Neurosciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences GmbH filed Critical Evotec Neurosciences GmbH
Publication of DE602006019582D1 publication Critical patent/DE602006019582D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/101Sanger sequencing method, i.e. oligonucleotide sequencing using primer elongation and dideoxynucleotides as chain terminators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602006019582T 2005-06-16 2006-06-14 Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen Active DE602006019582D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69086205P 2005-06-16 2005-06-16
EP05105316 2005-06-16
PCT/EP2006/063215 WO2006134128A2 (en) 2005-06-16 2006-06-14 Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases

Publications (1)

Publication Number Publication Date
DE602006019582D1 true DE602006019582D1 (de) 2011-02-24

Family

ID=35355216

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006019582T Active DE602006019582D1 (de) 2005-06-16 2006-06-14 Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen

Country Status (6)

Country Link
US (1) US20100008921A1 (de)
EP (1) EP1891241B1 (de)
JP (1) JP2008546379A (de)
AT (1) ATE495269T1 (de)
DE (1) DE602006019582D1 (de)
WO (1) WO2006134128A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2162550B1 (de) * 2007-06-13 2017-08-09 Alcediag Periphere gewebeprobe mit 5htr2c und/oder adar exprimierenden zellen als marker für die änderung des mechanismus der 5htr2c-mrna-prozessierung sowie anwendungen davon
WO2009007934A2 (en) 2007-07-10 2009-01-15 Neurim Pharmaceuticals (1991) Ltd. Cd44 splice variants in neurodegenerative diseases
EP2202321A1 (de) * 2008-12-17 2010-06-30 Biocortech Beurteilung des potentiellen Risikos von durch Arzneimittel ausgelösten Stimmungsstörungen und Selbstmord, Verwendung einer dafür vorgesehenen Plattform
US10456493B2 (en) 2017-06-23 2019-10-29 Allied Bioscience, Inc. Infection control apparatus

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763174A (en) * 1994-02-17 1998-06-09 The Wistar Institute Of Anatomy & Biology RNA editing enzyme and methods of use thereof
DE4438391C2 (de) 1994-10-27 1997-07-03 Evotec Biosystems Gmbh Vorrichtung zur Bestimmung stoffspezifischer Parameter eines oder weniger Moleküle mittels Korrelations-Spektroskopie
EP0836090A1 (de) 1996-10-12 1998-04-15 Evotec BioSystems GmbH Probenanalyseverfahren durch Bestimmung der spezifischen Helligkeitsverteilung von Teilchen
DE19649048C1 (de) 1996-11-27 1998-04-09 Evotec Biosystems Gmbh Verfahren zur Unterscheidung oder Erfassung von Partikeln in einer Probe durch Identifizierung von Signalabschnitten zeitaufgelöster, optischer Rohsignale aus der Probe auf Basis von Einzelphotonendetektion
EP0945718A1 (de) 1998-03-21 1999-09-29 Evotec BioSystems AG Ein Verfahren zur Probencharakterisierung durch Bestimmung einer Funktion mindestens einer spezifischen Eigenschaft von Einheiten der Probe
ATE208037T1 (de) 1997-12-23 2001-11-15 Evotec Biosystems Ag Verfahren zum nachweis von reaktionen mittels koinzidenzanalyse
WO2000052451A1 (en) 1999-03-03 2000-09-08 Evotec Analytical Systems Gmbh Homogeneous fluorescence assay
DK1175602T3 (da) 1999-04-29 2003-05-26 Evotec Ag Fremgangsmåde til karakterisering af fluorescente molekyler eller andre partikler, der anvender frembringerfunktioner
WO2001059416A1 (en) 2000-02-10 2001-08-16 Evotec Oai Ag Fluorescence intensity multiple distributions analysis: concurrent determination of diffusion times and molecular brightness
US6690463B2 (en) 2000-02-10 2004-02-10 Evotec Biosystems Ag Fluorescence intensity and lifetime distribution analysis
DE10030798A1 (de) 2000-06-29 2002-01-10 Evotec Analytical Sys Gmbh Kompetitives Assay-Verfahren
EP1313876B8 (de) 2000-08-11 2007-02-28 Evotec AG Verfahren zum nachweis von acetylase oder deacetylase aktivität in einem immunoassay

Also Published As

Publication number Publication date
ATE495269T1 (de) 2011-01-15
EP1891241B1 (de) 2011-01-12
EP1891241A2 (de) 2008-02-27
JP2008546379A (ja) 2008-12-25
US20100008921A1 (en) 2010-01-14
WO2006134128A2 (en) 2006-12-21
WO2006134128A3 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
WO2005108999A3 (en) Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease
ATE530667T1 (de) Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit
ATE461941T1 (de) Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
ATE361067T1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
WO2003028543A3 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
DE602006019582D1 (de) Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen
WO2004070388A8 (en) Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases
WO2006091964A3 (en) Regulators of protein misfolding and aggregation and methods of using the same
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
WO2002016636A3 (en) Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders
ATE534751T1 (de) Verwendung von prkx zur diagnose und therapie von alzheimer krankheit
ATE449964T1 (de) DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN
WO2004038411A3 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
ATE458834T1 (de) Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten
WO2006131562A3 (en) Diagnostic and therapeutic target cdc2l6 gene and proteins for neurodegenerative diseases
DE60235996D1 (de) Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen
WO2005030947A3 (en) Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases
WO2005101014A3 (en) Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases
WO2005059562A3 (en) Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases
ATE316657T1 (de) Diagnostische und therapeutische verwendung des caps
DE60314497D1 (de) Diagnostische und therapeutische verwendung von humanen maguinproteinen und nukleinsäuren bei neurodegenerativen krankheiten
WO2006008294A3 (en) Diagnostic and therapeutic use of slim3 for neurodegenerative diseases
WO2003085131A3 (en) Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases
DE60227650D1 (de) Verwendung eines zum kern beschränkten protein für die diagnose und therapie von alzheimer-krankheit und relatierte neurodegeneratiefe störungen

Legal Events

Date Code Title Description
R082 Change of representative

Ref document number: 1891241

Country of ref document: EP

Representative=s name: VON KREISLER SELTING WERNER, DE